CRISPR Therapeutics AG (CRSP) Cash from Investing Activities (2015 - 2026)

CRISPR Therapeutics AG has disclosed Cash from Investing Activities across 12 years of filings, most recently posting -$410.7 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$410.7 million, down 1979.19% year-over-year; the trailing twelve-month figure through Mar 2026 was -$422.8 million (down 108.85% YoY), and the FY2025 annual result was -$31.8 million, up 88.66% from the prior year.
• Cash from Investing Activities came in at -$410.7 million for Q1 2026 at CRISPR Therapeutics AG, down from $37.2 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $216.9 million in Q2 2023 to a low of -$410.7 million in Q1 2026.
• The 5-year median for Cash from Investing Activities is -$56.1 million (2022), against an average of -$35.7 million.
• Across the five-year window, Cash from Investing Activities jumped 486.87% in 2023 and sank 1979.19% in 2026, its largest moves.
• CRISPR Therapeutics AG's Cash from Investing Activities stood at -$175.5 million in 2022, then jumped by 53.6% to -$81.5 million in 2023, then surged by 229.93% to $105.8 million in 2024, then slumped by 64.85% to $37.2 million in 2025, then slumped by 1204.18% to -$410.7 million in 2026.
• The last three Cash from Investing Activities figures came in at -$410.7 million (Q1 2026), $37.2 million (Q4 2025), and -$119.2 million (Q3 2025), per Business Quant data.